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Purpose: The purpose of this study was to examine differences between patients clinically 
diagnosed with COPD with and without obstruction by spirometry and to identify risk factors 
for respiratory hospitalizations.
Materials and methods: This is a retrospective analysis of all patients diagnosed with COPD 
at a large academic Internal Medicine Clinic in 2014, who had spirometry performed during the 
period 2013–2014. Two groups existed: one with obstruction termed classical COPD and another 
without obstruction. Demographics, comorbidities, prescribed medications, spirometry, respira-
tory hospitalization, and eosinophilia among other variables were compared between patients 
with and without obstruction. Risk factors for two or more respiratory hospitalizations during the 
period 2014–2015 were sought for both populations by both univariate and multivariate analyses. 
Subsequently, we studied the population without obstruction for risk factors for one or more 
respiratory hospitalizations first by univariate analysis and then by multivariate analysis.
Results: Among 657 patients, 210 met inclusion criteria, with 157 having obstruction on 
spirometry and 53 without obstruction. There was no difference between those with and without 
obstruction on the rate of respiratory hospitalization when using two or more respiratory hospital-
izations (p=0.397) or one or more respiratory hospitalizations (p=0.467). Nontreatment risk factors 
associated with two or more respiratory hospitalizations by multivariate analysis included a maxi-
mum eosinophil count above the threshold of 0.5 K/µL (maximum eosinophil number threshold 
[MENT]; p=0.001, OR =3.792, 95% CI =1.676–8.582) and % predicted forced expiratory volume 
in the first second (p=0.031, OR =0.978, 95% CI =0.959–0.998). In patients without obstruction, 
MENT above the threshold of 0.5 K/µL (p=0.032, OR =5.087, 95% CI =1.147–22.557) was the 
only risk factor associated with one or more respiratory hospitalizations.
Conclusion: In a clinically diagnosed COPD population who had spirometry performed, the 
presence of airflow obstruction was not a risk factor for respiratory hospitalizations. The most 
significantly associated nontreatment factor associated with respiratory hospitalization, both 
in the study population as a whole and in the cohort without obstruction, was MENT above 
the threshold of 0.5 K/µL.
Keywords: chronic obstructive pulmonary disease, airflow obstruction, spirometry, eosinophilia
Introduction
COPD is a highly prevalent respiratory condition with substantial attributable morbidity 
and mortality. In the USA, COPD affects 24 million adults and is predicted to be the 
third leading cause of death by 2020.1,2 The economic burden of COPD is substantial, 
with US estimated medical costs in 2020 projected to be ~$49 billion.3 Exacerbations 
of disease account for 50% of the medical costs in the developed nations and also 
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negatively impact the trajectory of this chronic disease.4,5 
The prevention of exacerbations, especially hospitaliza-
tions resulting from COPD exacerbations, has become a 
focus for policy makers and a subject of clinical practice 
guidelines.6,7
COPD has traditionally been diagnosed in patients 
with obstructive physiology as measured by spirometry 
and with a compatible clinical history of smoking or other 
risk factors.8 Risk factors for exacerbations of COPD have 
been shown to include the severity of COPD and a history 
of exacerbations.9,10 Recently, there has been increased 
awareness that some patients with a history of smoking have 
clinical signs and symptoms consistent with a diagnosis 
of COPD without having obstruction demonstrated on 
spirometry.11,12 Practitioners caring for patients with chronic 
respiratory illness may manage patients diagnosed with 
COPD who may not have airflow obstruction on spirometry. 
The goal of reducing respiratory exacerbations leading to 
hospitalization in a heterogeneous outpatient population 
clinically diagnosed with COPD is challenging because 
the management of patients diagnosed with COPD without 
spirometric evidence of obstruction is not well defined and 
the rate and risk factors for hospitalization for respiratory 
problems in such patients are not well understood.
We chose to study a population of patients from an 
academic Internal Medicine Clinic over a 3-year period 
diagnosed with COPD by their health care provider. We 
included patients who had spirometry performed and used 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD)’s classical threshold of forced expiratory volume 
in the first second (FEV
1
)/forced vital capacity (FVC) 70% 
to determine whether obstruction was present or absent.8 We 
compared patients who had obstruction on spirometry with 
those who did not in terms of demographics, comorbidities, 
spirometry, eosinophilia, treatment, and hospitalization for 
respiratory problems. We hypothesized that patients with 
spirometric evidence of obstruction would be more likely 
to have hospitalization for respiratory problems compared 
with those who did not. We subsequently examined the study 
population for the association of risk factors with hospitaliza-
tion for respiratory problems.
Materials and methods
study design and patients
The Henry Ford COPD K15 Study was a single-center retro-
spective observational study performed at an academic urban 
tertiary care center located in Detroit, MI, USA. The study 
was approved by Henry Ford Hospital Institutional Review 
Board (#10889; assessing clinical factors in patients having 
COPD and the impact it has on both emergency department 
visits and hospital admissions). A waiver for informed 
consent was obtained as the study posed a minimal risk to 
all the subjects involved, with no patient interaction and no 
compromise in patient rights or welfare. Patient confidenti-
ality was maintained through password protected computer 
files to store data and e-mail exchange involving password 
protection and encryption. The study population included 
all patients participating in an academic Internal Medicine 
Clinic in 2014 with the International Classification of Dis-
eases, Ninth Revision, diagnosis of COPD (Table S1) who 
had spirometry performed within the institutional database 
for the period 2013–2014. Subjects with active malignancy 
(other than stable prostate cancer) and a history of organ 
transplantation were excluded.
Data collection and variables
Spirometry and demographics were extracted from a pulmo-
nary function test database for the period 2013–2014. The def-
inition of obstructive versus nonobstructive diseases as well 
as the severity of COPD was taken from the GOLD.8 Hospital 
admission data for the period 2014–2015 were extracted 
from the electronic medical record (EMR), after which 
EMR review was performed using diagnosis-related group 
codes to identify hospitalization for respiratory problems 
(Table S2). Pharmaceutical data for all outpatient medications 
prescribed in the period 2014–2015 were extracted using a 
pharmaceutical database. Medications were categorized into 
COPD-relevant pharmaceutical classes. EMR review for the 
period 2014–2015 was performed to extract patient-specific 
data, including the history of cardiac disease, asthma, chronic 
kidney disease, active malignancy, and transplantation; 
chronic oral glucocorticoid use; the maximum eosinophil 
percentage; and the maximum eosinophil count.
Definitions
Based on the presence or absence of obstruction, subjects 
were categorized as either having classical COPD or hav-
ing nonobstructive pulmonary disease. The classical COPD 
cohort was defined as having obstruction on spirometry using 
GOLD’s criteria of FEV
1
/FVC 70%.8 The nonobstructive 
cohort did not meet GOLD’s criteria of FEV
1
/FVC 70% 
for obstruction,8 however received a clinical diagnosis of 
COPD by a board-certified internal medicine specialist, likely 
due to a similar clinical presentation. Comorbidities were 
defined as being present if listed in a physician problem list 
during the study period. Chronic steroid use was defined as 
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prescription of oral corticosteroids other than for an acute 
exacerbation of COPD. Macrolide use was defined as an 
extended prescription of a macrolide other than for an 
acute exacerbation of COPD. Maximum eosinophil number 
(MEN) and maximum eosinophil percentage (MEP) of the 
total white blood count are the maximum values reported 
for each of these variables during the period 2014–2015 for 
each patient. The MEN 0.5 K/µL (maximum eosinophil 
number threshold [MENT]) is a dichotomous variable indi-
cating whether or not a patient’s maximum value equaled or 
exceeded the threshold value during the period 2014–2015. 
The threshold was chosen by studying the relationship of 
the MEN to hospitalizations for respiratory problems by the 
examination of the patient’s data. Pulmonary function test 
results are reported as the results % predicted compared with 
a standard population.13
statistical analysis
We performed all statistical analyses by using SPSS software 
Version 18 (SPSS Inc., Chicago, IL, USA) with a logistical 
regression add-on package Version 20 (IBM, Armonk, NY, 
USA) and considered p0.05 to be statistically significant 
unless otherwise specified. We used χ2 tests, two-sample 
t-tests, or Mann–Whitney U tests, as appropriate for uni-
variate analysis. Adjustments were not made for multiple 
comparisons.
Associations between risk factors and two or more hos-
pitalizations for respiratory problems were studied in the 
study group first by using a univariate analysis. Nontreat-
ment risk factors were chosen for a multivariate analysis if 
they were associated with respiratory hospitalizations at a 
significance level of p0.1. MENT, MEN, and MEP dem-
onstrated collinearity in a correlation matrix, and therefore, 
only the former was included in the analysis. Results were 
considered to be significant in the multivariate analysis if 
a p0.05 was found. The same strategy was applied to the 
study of associations between risk factors and all respiratory 
hospitalizations in the nonobstructed cohort. Respiratory 
hospitalization was chosen rather than two or more hospi-
talizations for respiratory problems in the nonobstructed 
cohort because of the small number of patients with multiple 
respiratory hospitalizations.
Results
Of 657 patients visited the Internal Medicine Clinic during 
2014 diagnosed with COPD, 242 patients (36.8%) had 
spirometry performed in the period 2013–2014. A total of 
210 subjects were included in the study population among 
whom 157 had airflow obstruction and 53 did not (selection 
algorithm, Figure S1). Table 1 demonstrates comparisons 
of study variables between those patients with and without 
obstruction. Table 2 displays the study population catego-
rized by the GOLD stage8 with the rate of exacerbation lead-
ing to hospitalization indicated for each group.
We assessed the study population for risk factors asso-
ciated with two or more hospitalizations for respiratory 
problems. A univariate analysis was performed for nontreat-
ment (Table 3) and treatment (Table 4) risk factors with 
two or more respiratory hospitalizations as the outcome 
variable. We then performed a multivariate analysis with 
two or more respiratory hospitalizations as the outcome 
variable and considering MENT, male gender, and FEV
1
 
% predicted as nontreatment risk factors. Of 210 patients, 
188 were included in the analysis, with 22 cases excluded 
for missing MENT data. MENT above the threshold of 0.5 
K/µL (p=0.001, OR =3.792, 95% CI =1.676–8.582) and % 
predicted FEV
1
 (p=0.031, OR =0.978, 95% CI =0.959–0.998) 
were significantly associated with two or more respiratory 
hospitalizations in the model, whereas male gender (p=0.097, 
OR =1.874, 95% CI =0.892–3.937) was not.
We extended our analysis to the cohort of the study popula-
tion that did not have obstruction. In the nonobstructed cohort, 
16 patients had one or more respiratory hospitalizations, and 
7 patients had two or more respiratory hospitalizations. We 
used one or more respiratory hospitalizations as the outcome 
variable for the nonobstructed cohort and considered nontreat-
ment (Table 5) and treatment (Table 6) risk factors in univariate 
analyses. We then performed a multivariate analysis with one 
or more respiratory hospitalizations as the outcome variable 
and considering MENT and FEV
1
 % predicted as nontreatment 
risk factors. MENT above the threshold of 0.5 K/µL (p=0.032, 
OR =5.087, 95% CI =1.147–22.557) was significantly associ-
ated with one or more respiratory hospitalizations in the model, 
whereas % predicted FEV
1
 (p=0.147, OR =0.971, 95% 95% 
CI =0.934–1.010) was not.
Among 37 patients in the study population with an 
increased MENT, 76% were prescribed inhaled corticosteroid 
(ICS) and 16% had a codiagnosis of asthma. Of 7 patients 
not prescribed ICS in this group, 5 patients had no respira-
tory hospitalizations.
Discussion
The most important findings of this retrospective study of 
a clinically diagnosed population of patients with COPD 
were that the FEV
1
/FVC ratio was not closely associated 
with respiratory hospitalization, whereas a close association 
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Table 1 Baseline characteristics: classical COPD versus nonobstructed group
Variable (n=210) Classical COPD  
(n=157)
Nonobstructed  
(n=53)
Level of significance 
(p0.05)
age in years (mean ± sD) 68±10 64±11 p=0.028**
active smoking 85/157 (54%) 28/53 (53%) p=0.869*
Male gender 76/157 (48%) 15/53 (28%) p=0.011*
african american 135/157 (86%) 46/53 (87%) p=0.883*
Body surface area (mean ± sD) 1.91±0.29 2.04±0.29 p=0.007**
Body mass index (mean ± sD) 28.5±8.25 34.9±9.87 p0.001**
history of cardiac disease 78/157 (50%) 21/53 (40%) p=0.205*
history of asthma 23/157 (15%) 5/53 (9%) p=0.334*
history of CKD 39/157 (25%) 7/53 (13%) p=0.077*
Chronic steroid use 3/157 (2%) 2/53 (4%) p=0.442*
laMa 109/157 (69%) 22/53 (42%) p0.001*
saMa 82/157 (52%) 24/53 (45%) p=0.382*
saBa 132/157 (84%) 41/53 (77%) p=0.267*
laBa 10/157 (6%) 1/53 (2%) p=0.205*
saBa + saMa 61/157 (39%) 23/53 (43%) p=0.559*
laBa + ICs 112/157 (71%) 27/53 (51%) p=0.007*
ICs 34/157 (22%) 13/53 (25%) p=0.664*
leukotriene receptor antagonist 7/157 (4%) 2/53 (4%) p=0.831*
Macrolide 69/157 (44%) 24/53 (45%) p=0.866*
Phosphodiesterase inhibitor 3/157 (2%) 0/53 (0%) p=0.311*
Methylxanthines 8/157 (5%) 0/53 (0%) p=0.094*
FVC % predicted (mean ± sD) 77.9±19.5 72.9±19.0 p=0.105**
FeV1 % predicted (mean ± sD) 52.3±18.4 71.0±17.9 p0.001**
FeV1/FVC (mean ± sD) 51.4±12.8 76±4.9 p0.001**
TlC % predicted (mean ± sD)a 105±19.3 76.4±18.7 p0.001**
DlCO % predicted (mean ± sD)b 51.7±19.6 61.4±16.2 p=0.003**
MenT 0.5 K/µlc 72.9±19.0 72.9±19.0 p=0.357*
MeP (%)c 4.66±4.46 5.16±5.79 p=0.550**
Men (K/µl)c 0.325±0.373 0.411±0.438 p=0.198**
1 respiratory hospitalization 56/157 (36%) 16/53 (30%) p=0.467*
2 respiratory hospitalization 32/157 (20%) 8/53 (15%) p=0.397*
Notes: *χ2 analysis; **student’s t-test analysis; an=25 in obstructed group and n=17 in nonobstructed group; bn=126 in obstructed group and n=46 in nonobstructed group; 
cn=143 in obstructed group and n=45 in nonobstructed group. Bold text indicates p0.05.
Abbreviations: CKD, chronic kidney disease; DlCO, diffusing capacity of the lungs for carbon monoxide; FVC, forced vital capacity; FeV1, forced expiratory volume 
in the first second; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic agent; MEN, maximum eosinophil number; MENT, 
maximum eosinophil number threshold; MeP, maximum eosinophil percentage; saBa, short-acting beta-agonist; saMa, short-acting muscarinic agent; TlC, total lung 
capacity.
Table 2 gOlD8 classification and the rate of hospital admission for respiratory illness
GOLD classification  
of obstruction
Number  
of patients
At least one  
admission  
(number of patients)
At least one  
admission,  
% of group*
At least two  
admissions  
(number of patients)
At least two 
admissions,  
% of group*
none 53 15 28 8 15
Mild 14 4 29 2 7
Moderate 71 22 31 13 15
severe 55 23 42 11 18
Very severe 17 7 41 6 24
Note: *Differences among groups were not significant.
Abbreviation: gOlD, global Initiative for Chronic Obstructive lung Disease.
was demonstrated between elevated serum eosinophils and 
respiratory hospitalization in all groups of patients. We 
demonstrated specific differences between obstructed and 
nonobstructed COPD patients in terms of demographics 
and treatment, but both groups had high rates of respiratory 
hospitalization. While there was a trend toward increased 
respiratory hospitalizations in patients with more severe 
COPD by GOLD stage of disease, the differences between 
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1065
risk factors for respiratory hospitalizations in COPD patients
Table 3 Univariate association of nontreatment risk factors with at least two respiratory hospitalizations
Variable Patients with  
2 hospitalizations  
(n=40)
Patients with  
1 hospitalization  
(n=170)
Level of  
significance 
(p0.05)
age in years (mean ± sD) 66±9.6 67±11 p=0.492**
active smoking 23/40 (58%) 90/170 (53%) p=0.603*
Male gender 23/40 (58%) 68/170 (40%) p=0.044*
african american 36/40 (90%) 145/170 (85%) p=0.438*
Body surface area (mean ± sD) 1.93±0.319 1.95±0.291 p=0.657**
Body mass index (mean ± sD) 29.6±11.1 30.2±8.60 p=0.714**
history of cardiac disease 23/40 (58%) 76/170 (45%) p=0.145*
history of asthma 3/40 (8%) 25/170 (15%) p=0.228*
history of CKD 9/40 (23%) 37/170 (22%) p=0.919*
FVC % predicted (mean ± sD) 73.0±2.8 77.5±18.6 p=0.188**
FeV1 % predicted (mean ± sD) 50.8±9.7 58.5±19.8 p=0.028**
FeV1/FVC (mean ± sD) 55.3±17.0 58.1±15.3 p=0.290***
FeV1/FVC 70% 32/40 (80%) 125/170 (74%) p=0.397*
TlC % predicted (mean ± sD)a 90.3±35.1 94.7±19.6 p=0.614**
DlCO % predicted (mean ± sD)b 51.7±23.9 54.9±17.9 p=0.385**
MenT 0.5 K/µlc 15/40 (38%) 22/148 (15%) p=0.001*
MeP (%)c 6.30±6.182 4.37±4.281 p=0.024**
Men (K/µl)c 0.477±0.539 0.310±0.334 p=0.020***
Notes: *χ2 analysis; **student’s t-test analysis; ***Mann–Whitney U test; an=10 with 2 hospitalizations and n=32 with 1 hospitalization; bn=33 with 2 hospitalizations 
and n=139 with 1 hospitalization; cn=40 with 2 hospitalizations and n=148 with 1 hospitalization. Bold text indicates p0.05.
Abbreviations: CKD, chronic kidney disease; DlCO, diffusing capacity of the lungs for carbon monoxide; FVC, forced vital capacity; FeV1, forced expiratory volume in the 
first second; MEN, maximum eosinophil number; MENT, maximum eosinophil number threshold; MEP, maximum eosinophil percentage; TLC, total lung capacity.
Table 4 Univariate association of treatment risk factors with at least two respiratory hospitalizations
Variable Patients  
with 2  
hospitalizations
Patients  
with 1  
hospitalization
Level of  
significance 
(p-value)
Chronic steroid use 1/40 (3%) 4/170 (2%) 0.956*
laMa 32/40 (80%) 99/170 (58%) 0.011*
saMa 37/40 (93%) 69/170 (41%) 0.001*
saBa 35/40 (88%) 138/170 (81%) 0.345*
laBa 6/40 (15%) 5/170 (3%) 0.002*
saBa + saMa 35/40 (88%) 49/170 (29%) 0.001*
laBa + ICs 34/40 (85%) 105/170 (62%) 0.005*
ICs 16/40 (40%) 31/170 (18%) 0.003*
leukotriene receptor antagonist 4/40 (10%) 5/170 (3%) 0.047*
Macrolide 28/40 (70%) 65/170 (38%) 0.001*
Phosphodiesterase inhibitor 2/40 (5%) 1/170 (1%) 0.034*
Methylxanthines 2/40 (5%) 6/170 (4%) 0.662*
Notes: *χ2 analysis. Bold text indicates p0.05.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting beta-agonist; laMa, long-acting muscarinic agent; saBa, short-acting beta-agonist; saMa, short-acting 
muscarinic agent.
groups did not achieve statistical significance. The nontreat-
ment risk factors most closely associated with more than two 
respiratory hospitalizations were MEN, MEP, and MENT. 
MENT was the risk factor most closely associated with two 
or more respiratory hospitalizations when controlling for 
other risk factors by multivariate analysis and was the only 
nontreatment risk factor associated with respiratory hospital-
ization in the cohort of patients without obstruction.
The definition of COPD has classically included the 
presence of obstruction as measured by spirometry, and 
disease severity has been categorized based on the degree 
of obstruction.14,15 This view has been challenged by the 
recognition that the presence of obstruction by spirometry 
is not a highly accurate independent risk factor for clinical 
outcomes and that consideration of other factors improves 
outcome prediction.8,16 When considering exacerbations of 
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COPD, severity of disease as defined by the GOLD clas-
sification has been shown to be a predictor of the rate of 
exacerbations.17,18 However, the data suggest that patients 
clinically diagnosed with COPD without airflow obstruction 
are not simply at risk of developing COPD but may also have 
clinically significant disease with respiratory symptoms.11,12 
In our study population, we found that there was a trend 
toward increased respiratory hospitalizations (Table 2) as the 
severity of COPD as indicated by the GOLD classification 
increased. This did not reach significance, probably because 
of the size of our study group. Obstruction by spirometry, 
as defined by a decreased FEV
1
/FVC ratio, was not a risk 
factor for two or more respiratory hospitalizations, although 
there was a weak association between a low FEV
1
 and two 
Table 5 Univariate association of nontreatment risk factors with at least one respiratory hospitalization in patients without obstruction 
by spirometry
Variable Patients with  
1 hospitalization  
(n=16)
Patients with  
no hospitalization  
(n=37)
Level of  
significance 
(p0.05)
age in years (mean ± sD) 65±12 63±11 p=0.503**
active smoking 10/16 (63%) 18/37 (49%) p=0.354*
Male gender 6/16 (38%) 9/37 (24%) p=0.328*
african american 15/16 (94%) 31/37 (84%) p=0.325*
Body surface area (mean ± sD) 2.01±0.338 2.05±0.274 p=0.639**
Body mass index (mean ± sD) 34.8±13.3 34.9±8.17 p=0.965**
history of cardiac disease 7/16 (44%) 17/37 (46%) p=0.883*
history of asthma 1/16 (6%) 7/37 (19%) p=0.237*
history of CKD 1/16 (6%) 8/37 (22%) p=0.171*
FVC % predicted (mean ± sD) 65.7±21.6 76.0±17.2 p=0.069**
FeV1 % predicted (mean ± sD) 64.3±19.3 74.0±16.6 p=0.068**
FeV1/FVC (mean ± sD) 76.3±5.33 75.9±4.69 p=0.824***
TlC % predicted (mean ± sD)a 66.7±20.5 81.6±16.3 p=0.118**
DlCO % predicted (mean ± sD)b 61.9±16.5 61.2±16.3 p=0.889**
MenT 0.5 K/µlc 7/16 (44%) 4/29 (14%) p=0.025*
MeP (%)c 5.94±4.155 4.72±6.546 p=0.507**
Men (K/µl)c 0.532±0.4223 0.344±0.440 p=0.054**
Notes: *χ2 analysis; **student’s t-test analysis; ***Mann–Whitney U test; an=6 with 1 hospitalization and n=11 with no hospitalization; bn=12 with 1 hospitalization and 
n=34 with no hospitalization; cn=16 with 1 hospitalization and n=29 with no hospitalization. Bold text indicates p0.05.
Abbreviations: CKD, chronic kidney disease; DlCO, diffusing capacity of the lungs for carbon monoxide; FVC, forced vital capacity; FeV1, forced expiratory volume in the 
first second; MEN, maximum eosinophil number; MENT, maximum eosinophil number threshold; MEP, maximum eosinophil percentage; TLC, total lung capacity.
Table 6 Univariate association of treatment risk factors with 1 respiratory hospitalization in patients without obstructive by 
spirometry
Variable Patients with  
1 hospitalization  
(n=16)
Patients with  
no hospitalization  
(n=37)
Level of  
significance 
(p0.05)
Chronic steroid use 1/16 (6%) 1/37 (3%) p=0.534*
laMa 10/16 (63%) 12/37 (32%) p=0.041*
saMa 13/16 (81%) 11/37 (30%) p0.001*
saBa 13/16 (81%) 28/37 (76%) p=0.656*
laBa 1/16 (6%) 1/37 (3%) p=0.125*
saBa + saMa 14/16 (88%) 9/37 (24%) p0.001*
laBa + ICs 12/16 (75%) 15/37 (41%) p=0.021*
ICs 5/16 (31%) 8/37 (22%) p=0.455*
leukotriene receptor antagonist 1/16 (6%) 1/37 (3%) p=0.534*
Macrolide 10/16 (63%) 14/37 (38%) p=0.098*
Phosphodiesterase inhibitor 0/16 (0%) 0/37 (0%) n/a
Methylxanthines 0/16 (0%) 0/37 (0%) n/a
Notes: *χ2 analysis. Bold text indicates p0.05.
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting beta-agonist; laMa, long-acting muscarinic agent; saBa, short-acting beta-agonist; saMa, short-acting 
muscarinic agent; n/a, no comparison.
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long-acting beta-agonist (LABA), and ICS, prevent acute 
exacerbations of COPD.7 In our study population of patients 
with COPD, we found that the prescription of multiple agents 
was positively associated with respiratory hospitalization 
(Tables 4 and 6). We believe that the most likely reason for 
this finding is that clinicians-treated patients thought to be at 
risk for respiratory hospitalization more aggressively and with 
more agents compared with those thought not to be at risk. Our 
study was retrospective, and in the absence of treatment pro-
tocols or algorithms, clinician’s prescribing practices were not 
controlled. An alternative explanation that these agents caused 
respiratory hospitalization in the study population seems very 
unlikely given the known effects of these drugs.7 Patients in 
the study population without obstruction by spirometry were 
often treated with bronchodilator and anti-inflammatory 
agents, though not to the same extent as those with obstruction 
(Table 1). The data are extremely limited regarding appropriate 
treatment regimens for patients with COPD without airflow 
obstruction, and further research is needed.11,12
Increased number and proportion of blood eosino-
phils have been associated with exacerbations of COPD 
in some but not all studies.22–24 Couillard et al found that 
55 of 167 patients with COPD had eosinophilia defined 
as 200 eosinophils/µL or 2% of the total leukocyte count 
during a respiratory hospital admission for COPD and that 
these patients had a 3-fold risk of respiratory hospitalization 
over the subsequent year as well as a shorter time to the next 
exacerbation.22 Vedel-Krough et al studied a large cohort 
of COPD patients from a population database in Copen-
hagen and determined that an eosinophil level 0.34×109 
cells/L was associated with a 1.76-fold increase of severe 
exacebations.23 On the other hand, Bafadhel et al examined 
243 COPD patients with respiratory hospitalization and 
determined that elevated eosinophil levels were not associ-
ated with an increased rate of respiratory hospitalization 
and that the mean length of stay for the index respiratory 
hospitalization was shorter than that of other patients.24 
COPD patients with eosinophilia have been postulated to 
be more responsive to corticosteroid treatment and to have 
better outcomes compared with other COPD patients.24–26 
We measured eosinophil levels in our study population and 
found that MEN, MEP, and MENT were associated with 
respiratory hospitalization both in the study population as a 
whole and in the cohort of patients without obstruction by 
spirometry. Our observations suggest that eosinophilia may 
be a risk factor for exacerbations of COPD in patients both 
with and without obstruction by spirometry. Most patients 
in our study population were prescribed either LABA/ICS or 
or more respiratory hospitalizations. We found a high rate of 
respiratory hospitalizations among patients diagnosed with 
COPD, but not having obstruction on spirometry. This find-
ing is consistent with the findings of other recent works11,12 
and suggests that future perspectives of smoking-related lung 
disease may need to incorporate such patients.
While guidelines continue to emphasize the need to obtain 
spirometry to confirm the diagnosis of COPD,8 practicing 
physicians often fail to comply with this recommendation.19 
Many patients with a diagnosis of COPD considered for 
our study did not have spirometry performed, a result that is 
consistent with that of Han et al, who found that only 32% 
of clinically diagnosed COPD patients from a large insur-
ance database had spirometry performed.19 The implication 
of these data is that clinicians are diagnosing patients with 
COPD in the absence of recent and regular spirometry 
measurements and are providing treatment based on clinical 
signs and symptoms. Our data concerning treatment reflect 
that treatment strategies prescribed for patients diagnosed 
with COPD without obstruction on spirometry are similar to 
that prescribed for patients with obstruction. More data are 
needed in patients with smoking-related lung disease without 
obstruction by spirometry to understand which medications 
and regimens lead to improved clinical outcomes.
We considered the possibility that a different comorbidity 
profile between the obstructed and nonobstructed patients in 
our study population could account for the lack of difference 
in respiratory hospitalization between the two groups. Ander-
sen et al have demonstrated in a population from Finland 
that patients with the COPD–asthma overlap syndrome have 
increased hospitalization rates when compared to patients with 
either COPD or asthma alone.20 Braunstein et al demonstrated 
that, in a population of elderly patients with chronic heart 
failure in the USA, the additional diagnosis of COPD was sig-
nificantly associated with an increased rate of hospitalization.21 
Among the patients in our study population, the prevalence of 
congestive heart failure, asthma, and chronic kidney was not 
different between the obstructed and nonobstructed groups, 
with trends toward a lesser prevalence of each comorbidity 
in the nonobstructed group. While this suggests that a differ-
ence in comorbidities does not account for the similarity in 
respiratory hospitalization rates between obstructed and non-
obstructed patients, our assessment is limited by the fact that 
comorbidity data were obtained by extraction from the EMR 
rather than from a comprehensive clinical assessment.
Criner et al performed a systematic review of the literature 
and demonstrated by a meta-analysis that multiple pharmaceu-
tical agents, including long-acting muscarinic agents (LAMA), 
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ICS, suggesting that the measurement of eosinophilia may be 
a useful marker even in patients receiving therapy.
Our study is limited by being a single-center retrospec-
tive study and the one that involves a largely urban and 
black population. Nearly two thirds of the available popula-
tion was excluded because spirometry was not performed 
by clinicians. No treatment algorithms were in place to 
standardize the management. These elements of our study 
may prevent others from generalizing our results to their 
patients. In addition, we accepted clinicians’ assignment of 
the diagnosis of COPD without imposing any other criteria. 
Although this approach may be relevant to the “real-world” 
management of such patients, it may have biased our patient 
selection toward patients with respiratory complaints and 
hospitalizations due to multiple causes and may be difficult 
to reproduce and apply in other practice settings.
Conclusion
In a population of patients diagnosed as having COPD by 
their clinician who had spirometry performed, the presence 
of airflow obstruction as measured by a reduced FEV
1
/FVC 
was not a risk factor for respiratory hospitalizations. The most 
significantly associated nontreatment factor associated with 
respiratory hospitalization, both in the study population as a 
whole and in the cohort without obstruction, was eosinophilia. 
Further research is needed to confirm these findings and to 
develop management strategies for COPD patients with 
eosinophilia and for those without airflow obstruction.
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Table S2 ICD-9 & Drg codes with description used to deter-
mine rh
ICD-9/DRG Description
415.19 Other pulmonary embolism and infarction
465.9 Acute upper respiratory infection or unspecified site
466 acute bronchitis
482.1 Pneumonia due to pseudomonas
482.9 Bacterial pneumonia, unspecified
486 Pneumonia, organism unspecified
487.1 Influenza with pneumonia
487 Influenza with other respiratory manifestations
491.21 Obstructive chronic bronchitis with acute exacerbation
492.8 Other emphysema
493.22 Chronic obstructive asthma with acute exacerbation
493.9 Asthma unspecified
493.92 Asthma, unspecified with acute exacerbation
494.1 Bronchiectasis with acute exacerbation
496 Chronic airway obstruction, not elsewhere classified
507 Pneumonitis due to inhalation of food or vomitus
511.89 Other specified forms of effusion, except tuberculosis
511.9 Unspecified pleural effusion
512 Pneumothorax
518.81 acute respiratory failure
518.84 acute and chronic respiratory failure
799.02 hypoxemia
a31.0 Pulmonary mycobacterial infection
J18.9 Pneumonia, unspecified organism
J40 Bronchitis, not specified as acute or chronic
J44.1 COPD with (acute) exacerbation
J96.21 acute and chronic respiratory failure with hypoxia
J96.22 acute and chronic respiratory failure with hypercapnia
J98.01 acute bronchospasm
Abbreviations: Drg, diagnosis-related group; ICD-9, the International Classi-
fication of Diseases, Ninth Revision; RH, respiratory hospitalization.
Supplementary materials
Table S1 ICD-9 codes with description used to determine 
COPD diagnosis within Internal Medicine Clinic
ICD-9 Description
491.2 Obstructive chronic bronchitis
492 emphysema
496 Chronic airway obstruction, not elsewhere classified
Abbreviation: ICD-9, Inter national Classification of Diseases, Ninth Revision.
Figure S1 selection algorithm.
Abbreviations: COPD, chronic obstructive pulmonary disease; IM Clinic, Internal 
Medicine Clinic; PFT, pulmonary function test.
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